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a b s t r a c t
FAS and FASLG genes are closely linked to the apoptosis mechanism of the immune system and several
polymorphisms in these genes have been associated with susceptibility to diseases. The present study
investigated the polymorphisms at positions −670 in the FAS gene, and −169 and −124 in the FASLG
gene, among HTLV-1 infected subjects. Blood samples from HTLV infected subjects and seronegative
individuals were collected, and polymorphisms were analyzed using a polymerase chain reaction (PCR)
followed by RFLP analysis using restriction endonucleases. The genotype frequencies of the FAS −670
polymorphism was the only one that showed a higher and signiﬁcant prevalence of genotype −670GG
amongHTLV-1 infected subjects as compared to the control group (p=0.0160), but the genotype −670AASP/HAM was more frequent among TSP/HAM patients as compared to the asymptomatic individuals (p=0.0005).
TCD4+ and TCD8+ lymphocyte counts from HTLV infected and seronegative subjects, as well as the provi-
ral load values, according to the status of symptomatic and asymptomatic infection carrying different
genotypes were compared but showed no statistical signiﬁcance. The present results suggest that FAS
−670 polymorphism seems to be associated with susceptibility to HTLV-1 and may increase the chance
to develop TSP/HAM among HTLV-1 infected persons.. Introduction
HumanT-cell lymphotropicvirus type1 (HTLV-1) is amemberof
he family Retroviridae, sub-family Oncovirinae, genus Deltaretro-
irus. It was isolated for the ﬁrst time in Japan, from patients with
dult T-cell leukemia (ATL) (Uchiyama et al., 1977). Subsequently,
he virus was associated with a neurological disease named Trop-
cal Spastic Paraparesis/HTLV-1 associated mielopathy – TSP/HAM
Osame et al., 1987), a chronic and progressive demyelinating dis-
ase associated to HTLV-1 infection which affects between 0.2 and
% of the infected individuals in the fourth decade of life (Kaplan
t al., 1990; Vernant et al., 1987).
Initial symptoms of TSP/HAM include weakness and stiffness of
he lower limbs, hyper-reﬂection of the lower limbs and Babinski
ign (Osame et al., 1987; Vernant et al., 1987) which progresses to
ack pain, a variable degree of sensory loss and bladder disorders
uch as urinary urgency and incontinence (Ferreira Júnior et al.,
997).
∗ Corresponding author. Tel.: +55 91 8115 8578.
E-mail address: vallinoto@ufpa.br (A.C.R. Vallinoto).
168-1702/© 2011 Elsevier B.V. Open access under the Elsevier OA license. 
oi:10.1016/j.virusres.2011.09.015© 2011 Elsevier B.V. Open access under the Elsevier OA license.
FAS (also known as TNFRSF6/CD95/APO-1) is a death domain-
containing member of the TNFR (Tumor Necrosis Factor Receptor)
superfamily that is involved in apoptotic signaling in several cell
types (Itoh et al., 1991; Oehm et al., 1992). It has a central role
in the physiological regulation of programmed cell death and has
been implicated in the pathogenesis of various malignancies and
diseases of the immune system. The FAS receptor induces an apop-
totic signal by binding to its ligand, FASL, expressed on the surface
of other cells (Baumann et al., 2002; Schmitz et al., 2003). The
human FAS gene, located on chromosome 10q24.1, consists of nine
exons and eight introns (Inazawa et al., 1992). One important poly-
morphism which has been identiﬁed in the FAS promoter region,
includesanA–Gsubstitutionatnucleotideposition−670 (FAS−670
A>G; rs 1800682) (Huang et al., 1997, 1999).
FASLG (FAS ligand, also known as TNFSF6/CD95LG) is a member
of the tumor necrosis factor superfamily and triggers the apop-
totic cell-death cascade by linking with its receptor. This ligand is
found attached to the cell membrane (40kDa) or in a soluble form
(28kDa), as a result from the cleavage of the 40kDa protein. The
human FASLG gene is located on chromosome 1q23, and consists
of four exons and three introns (Takahashi et al., 1994). Three poly-
morphisms have been reported within this gene, and two of them
s Rese
i
−
−
e
a
g
2
2
T
o
U
r
2
V
t
S
S
−
a
t
p
d
T
e
2
l
a
e
t
(
R
c
H
c
s
T
GA.C.R. Vallinoto et al. / Viru
nclude a T deletion in position −169 of intron 3 (FASLG IVS3nt
169 T>T; ni) and an A–G substitution at nucleotide position
124 of intron 2 (FASLG INV2nt −124 A>G; rs 5030772) (Bolstad
t al., 2000; Pinti et al., 2002; Zhang et al., 2006).
The present study intended to investigate the occurrence of FAS
ndFASLGpolymorphismsand its role in the susceptibility andpro-
ression to neurological disease among HTLV-1 infected persons.
. Methods
.1. HTLV-1 infected and seronegative controls
The study population included 66 HTLV-1 infected subjects (26
SP/HAM symptomatic and 40 asymptomatic) registered at the
utpatient clinic of the Tropical Medicine Nucleus of the Federal
niversity of Para and 192 seronegative controls. All individuals
esided in Belém, were recruited between May 2005 and January
010 and signed a consent term. Blood samples were collected in
acuntainer tubes containing K3-EDTA as anticoagulant in order
o obtain plasma and peripheral blood mononuclear cells (PBMC).
amples were directed to the Virus Laboratory of the Biological
ciences Institute of the Federal University of Para and stored at
20 ◦C before use. Samples were screened for anti-HTLV using
n enzyme-linked immunosorbent assay (Orhto Diagnostic Sys-
ems Inc., USA) and infection was conﬁrmed by a nested-PCR, as
reviously described (Vallinoto et al., 2002). The study was con-
ucted within a period of 18 months. The clinical diagnosis of
SP/HAM followed the criteria previously described (Castro-Costa
t al., 2006).
.2. Quantiﬁcation of HTLV-1 viral load and CD4+/CD8+ T
ymphocytes
The quantiﬁcation of HTLV proviral load was performed by
real-time PCR assay, as previously described (Tamegão-Lopes
t al., 2006). Blood samples were processed within 4h of collec-
ion and T-cell subset counts were determined by ﬂow cytometry
FacsCount, Becton & Dickinson, USA) using the FacsCountTM
eagents immunomonitoring kit, according to a standard proto-
ol recommended by the manufacturer (Becton & Dickinson, USA).
TLV-1 infected persons were tested for HTLV-1 proviral load and
ounting of CD4+ T lymphocytes at the time of entry into the
tudy.
able 1
enotype and allele frequencies of FAS and FASL polymorphisms among HTLV infected p
Genotype proﬁle HTLV patients
n (%)
Control group
n (%)
p*
FAS −670 A>G
AA 15(22.73) 37 (19.27) 0.0
AG 20(30.30) 96 (50.00)
GG 31(46.97) 59 (30.73)
A 0.3788 0.4427 0.4
*G 0.6212 0.5573
FASLG IVS2nt −124 A>G
AA 59(89.39) 159 (82.81) 0.3
AG 6(9.09) 31 (16.15)
GG 1(1.52) 2 (1.04)
*A 0.9394 0.9089 0.5
*G 0.0606 0.0911
FASLG IVS3nt −169 T>T
TT 51 (77.28) 153 (79.69) 0.7
TT 14 (21.21) 38 (19.79)
TT 1 (1.51) 1 (0.52)
T 0.8788 0.8958 0.8
*T 0.1212 0.1042
* Test G.arch 163 (2012) 178–182 179
2.3. Polymorphisms analysis
Genomic DNA was extracted from PBMC using the puriﬁcation
kit GFX for genomic DNA (Amersham Pharmacia Biotech, USA). FAS
and FASLG polymorphisms were identiﬁed using a PCR method.
Ampliﬁcation was performed in a ﬁnal volume of 30L containing
500ng of total DNA extracted, 0.2M of each dNTP, 5pmol/L of
each primer,MgCl2 2.0mM, 50mMKCl, Tris–HCl pH8.3 10mMand
1.0U of Taq DNA polymerase. The primers used for ampliﬁcation of
FAS and FASLG promoter regions were: 5′-CTA CCT AAG AGC TAT
CTA CCG TTC-3′ (forward) and 5′-GGC TGT CCA TGT TGT GGC TGC-
3′ (reverse) for FAS −670 A>G polymorphism; 5′-GCA GTT CAG ACC
TAC ATG ATT AGG AT-3′ (forward) and 5′-CCA ATT CTC ACC TGT
ACC TTC-3′ (reverse) for FASLG IVS2nt −124 A>G; 5′-AGG AAA GGA
CTT CAA AGC CTA-3′ (forward) and 5′-TTG ATG CAT CAC AGA ATT
TCG TC-3′ (reverse) for FASLG IVS3nt −169 T>T.
The ampliﬁcation reactions were performed under the follow-
ing conditions: (i) for the −670 A>G polymorphism followed initial
denaturation at 94 ◦C during 360 s, followed by 35 cycles of 60 s at
94 ◦C, 60 s at 50 ◦C and 60 s at 72 ◦C; (ii) for the −124 A>G polymor-
phism the reaction mixture was denaturared at 94 ◦C during 360 s,
followed by 35 cycles of 60 s at 94 ◦C, 60 s at 55 ◦C and 60 s at 72 ◦C;
(iii) for the −169 T>T polymorphism the reaction was initiated
by denaturation at 94 ◦C, followed by 35 cycles of 60 s at 94 ◦C, 60 s
at 51 ◦C and 60 s at 72 ◦C.
PCR products were digested with three restriction endonucle-
ases, MvaI, FokI and HincII, that can distinguish the FAS −670
A>G, FASLG IVS2nt −124 A>G and FASLG IVS3nt −169 T>T poly-
morphisms, respectively. The products of digestion included three
fragments (184, 47 and 101bp) for the −670 G allele, two frag-
ments (210, 29bp) for the −124 G allele, and two fragments (162
and 23bp) for the −169T allele.
Both PCR and RFLP products were visualized after electrophore-
sis (100V/45min) in a 4% agarose gel in 1× TAE buffer (40×
TAE stock – TrisBase 1.6M, Na acetate 0.8M and EDTA – Na2
40mM/1000mL deionized water) containing 5L of Syber Safe®,
using transillumination with a source of ultra-violet light.
2.4. Statistical analysisThe genotypic and allelic frequencies observed were obtained
by direct counting. The comparison between allele and genotype
frequencies were calculated using the G test. The association anal-
ysis between the genotype frequencies and the arithmetic average
ersons (TSP/HAM and asymptomatic) and a control group.
TSP/HAMn (%) Asymptomaticn (%) p*
160 11 (42.31) 4 (10.00) 0.0005
2 (7.69) 18 (45.00)
13 (50.00) 18 (45.00)
385 0.4615 0.3250 0.0671
0.5385 0.6750
743 23 (88.46) 36 (90.00) 0.6232
3 (11.54) 3 (7.50)
0 (0.00) 1 (2.50)
840 0.9423 0.9375 0.8771
0.0577 0.0625
665 17 (65.39) 34 (85.00) 0.1259
9 (34.61) 5 (12.50)
0 (0.00) 1 (2.50)
756 0.8269 0.9125 0.1123
0.1731 0.0875
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f the values of proviral load, as well as, the TCD4+ and TCD8+ lym-
hocyte counts were performed by the Mann–Whitney and Test-t,
espectively. The analysis and the Hardy–Weinberg equilibrium
ere calculated using the software BioEstat 5.0 (Ayres et al., 2007).
p value <0.05 was considered to be statistically signiﬁcant.
. Results
Allele frequency and genotype distribution of FAS and FASLG
enes of both HTLV infected and control groups are shown in
able 1. The allele frequency for FAS −670G was 0.6212 and
.5573 among HTLV patients and control subjects, respectively.
he frequencies for FASLG −124G and FASLG −169T were 0.0606
nd 0.1212 among HTLV infected subjects and 0.0911 and 0.1042
mong control group, respectively. The differences observed were
ot statistically signiﬁcant.
The genotype FAS −670GG was more frequent among HTLV
nfected subjects (46.97%) than in the control group (30.73%),
howing a difference which was statistically signiﬁcant (p=0.0160,
able 1).
The genotypic frequency observed among HTLV patients was
ot in Hardy–Weinberg equilibrium for −670 FAS polymorphism
p=0.0038), but it was in equilibrium for FASLG −124 and
ASLG −169 polymorphisms (p=0.1014, p=0.9721, respectively),
s well as within the control group for the three polymorphisms
p=0.8537, p=0.7242, p=0.4021; data not shown).
Theallele andgenotype frequencieswerealso comparedaccord-
ng to the presence or absence of overt disease clinically diagnosed
s TSP/HAM.
The allele frequencies for FAS −670G were 0.5385 and 0.6750
mongTSP/HAMandasymptomaticHTLV infectedpersons, respec-
ively. For FASLG −124G and FASLG −169T frequencies were
.0577and0.1731amongTSP/HAMpatients and0.0625and0.0875
mong asymptomatic subjects, respectively. The differences were
ot statistically signiﬁcant.
FAS polymorphism showed a higher prevalence of genotype
AS −670AA among TSP/HAM patients (42.3%), as compared to
symptomatic individuals (10%), a difference which was statisti-
ally signiﬁcant (p=0.0005; Table 1).
The average of TCD4+ and TCD8+ lymphocyte counts among
TLV patients and controls are shown in Table 2. No difference was
tatistically signiﬁcant. TCD4+ lymphocytes among HTLV infected
ubjects ranged from 581 to more than 2000 cells/L with an aver-
ge of 1164.81 cells/L, in comparison to a range from 428 to
ore than 2000 cells/L, with an average of 1059.59 cells/L, in
he control group. TCD8+ lymphocyte counts ranged from 188 to
673 cells/L, with an average of 623.67 cells/L, and from 162 to
368 cells/L with an average of 610.85 cells/L, respectively.
When thegroupof infectedpatientswasdividedbetweensymp-
omatic and asymptomatic subjects it was shown that among
symptomatic patients the count of TCD4+ cells ranged from 581
o more than 2000 cells/L with an average of 1233.96 cells/L.
mong TSP/HAM patients it ranged from 674 to 1883 cells/L
ith an average of 1095.65 cells/L. TCD8+ lymphocytes count in
symptomatic patients ranged from 297 to 1049 cells/L with an
verage of 670.77 cells/L. In TSP/HAM patients TCD8+ lympho-
ytes count ranged from 188 to 1673 cells/L with an average
f 576.57 cells/L. There were no statistically signiﬁcant differ-
nces. Furthermore, the differences between LTCD4+/LTCD8+ ratios
egarding the genotypes did not show statistical signiﬁcance.
Table 3 shows the average proviral load among TSP/HAM and
symptomatic subjects according to the genotype and allele fre-
uencies of FAS and FASLG polymorphisms. The statistical analysis
howed signiﬁcant difference regarding the presence or absence of
he mutant alleles to each one of the polymorphisms. Ta
b
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Table 3
Proviral load counts among TSP/HAM and asymptomatic individuals according to the genotype and allele frequencies of FAS and FASL polymorphisms.
Genotypes proﬁles TSP/HAM (n) Asymptomatic (n) p
Analyzed Proviral load Analyzed Proviral load
FAS −670 (A>G)
AA 11 1575.957 4 84.798 0.0265
AG+GG 15 769.803 36 229.488 <0.0001
FASLG IVS2nt −124 (A>G)
AA 23 1251.570 36 234.667 <0.0001
AG+GG 3 1167.253 4 50.913 0.0970
FASLG IVS3nt −169 (T >T)
TT 17 1320.432 34 242.092 <0.0001
TT+TT 9 1093.392 6 74.064 0.0169
Table 4
Combined genotypes frequencies of the FAS and FASL polymorphisms among HTLV patients and a control group as well as TSP/HAM and asymptomatic patients.
Associated genotypes HTLV patients n (%) Control group n (%) p* TSP/HAM n (%) Asymptomatic n (%) p*
FAS −670/FASLG IVS2nt −124
AA/AA 12 (18.18) 33 (17.19) 0.1964 9 (34.61) 3 (7.50) 0.0379
AA/GG+AG 3(4.55) 4 (2.08) 2 (7.69) 1 (2.05)
GG+AG/AA 47 (71.21) 126 (65.63) 14 (53.85) 33 (82.50)
GG+AG/GG+AG 4(6.06) 29 (15.10) 1 (3.85) 3 (7.50)
FAS −670/FASLG IVS3nt −169
TT/AA 14 (21.21) 30 (15.62) 0.3721 10 (38.46) 4 (10.00) 0.0030
TT/GG+AG 37(56.06) 123 (64.06) 7 (26.92) 30 (75.00)
TT+TT/AA 1(1.52) 7 (3.65) 1 (3.85) 0 (0.00)
TT+TT/GG+AG 14(21.21) 32 (16.67) 8 (30.77) 6 (15.00)
FASLG IVS2nt −124/FASLG IVS3nt −169
AA/TT 46 (69.70) 121 (63.02) 0.1502 15 (57.69) 31 (77.50) 0.3686
AA/TT+TT 13 (19.70) 38 (19.79) 8 (30.77) 5 (12.50)
a
T
n
a
(
u
4
m
t
g
F
s
t
p
c
c
e
a
−
t
(
2
F
1
w
a
m
H
cGG+AG/TT 5 (7.57) 32 (16.67)
GG+AG/TT+TT 2 (3.03) 1 (0.52)
* Test G.
Genotype polymorphisms of FAS and FASLG were grouped
ccording to HTLV infected patients and control group as well as
SP/HAM and asymptomatic patients (Table 4). Statistically sig-
iﬁcant associations were observed when combining FAS −670
nd FASL −124 (p=0.0379), as well as, FASLG −169 and FAS −670
p=0.0030),when comparing TSP/HAMandasymptomatic individ-
als.
. Discussion
The study examined the occurrence of single nucleotide poly-
orphism (SNP) in FAS and FASLG genes, and their association with
he susceptibility to HTLV-1 infection as well as to the risk of pro-
ression to TSP/HAM. The association of the genotypes for both
AS and FASLG polymorphisms may contribute to the prediction of
ome effector immune response to eliminate the virus or to render
he host susceptible to the development of TSP/HAM.
Previous studies have suggested that FAS promoter polymor-
hism are associated with the risk of diseases including cervical
arcinogenesis, esophageal squamous-cell carcinoma, prostate
ancer and squamous cell carcinoma of the head and neck (Zhang
t al., 2006; Ueda et al., 2005; Sun et al., 2004; Lima et al., 2008),
lthough some studies have reported no association between FAS
670 polymorphism and diseases like rheumatoid arthritis, sys-
emic lupus erythematosus, breast cancer and multiple sclerosis
Huanget al., 1999; Zhanget al., 2006; Sibley et al., 2003;Crewet al.,
007; Niino et al., 2002). In the present study, we observed that the
AS −670GG genotype showed a higher prevalence among HTLV-
infected persons than in controls, but the genotype FAS −670AA
as more frequent among TSP/HAM patients as compared to the
symptomatic individuals, suggesting that the FAS −670A/G poly-
orphism may be associated, not only with the susceptibility to
TLV infection, but alsowith the progression to TSP/HAM. The pro-
ess seems to be controlled by a two-step mechanism in which the2 (7.69) 3 (7.50)
1 (3.85) 1 (2.50)
alreadyHTLV-1 infected individuals carrying theFAS−670AAgeno-
type carry a great chance and a higher susceptibility to progress to
overt clinical disease such as TSP/HAM.
It is possible that the physical location of a SNP of FAS (−670A/G)
may favour its binding to the site of the signal traducer and acti-
vator of transcription (STAT1), and it would be sufﬁcient for the up
and down regulation of the expression of the FAS gene. The results
presented herein describe a strong association between this SNP
and HTLV infection and suggest that HTLV-1 infected subjects car-
rying by the FAS −670GG genotype may have a lower afﬁnity to
STAT1 binding as compared to subjects carrying the FAS −670AA
genotype. This could lead to a decrease or increase of the apoptotic
potential of the FAS receptor among patients carrying FAS −670GG
and AA genotypes, respectively, which corroborates a recent result
showing that this functional FAS promoter polymorphism is signif-
icantly associated to the susceptibility to HTLV-1 and to the clinical
manifestation and survival of HTLV-1 patients presenting adult T-
cell leukemia – ATL (Farre et al., 2008), although it remains unclear
how the presence of this polymorphism could inﬂuence the sus-
ceptibility to infection.
The analysis of 66HTLV-1 infected patients and 192 control sub-
jects showed that the FASLG −124 and −169 polymorphisms (both
located within intronic regions of the FASLG gene) are not asso-
ciated with the susceptibility to the infection. The analysis of the
same groups for the FAS −670A/G polymorphism showed associa-
tion with an increased risk for HTLV infection but not for the FASLG
gene polymorphisms. This polymorphism was initially described
among Sjögren’s syndrome patients (Bolstad et al., 2000) and few
studies have been reported about FASLG IVS2nt −124 and FASLG
IVS3nt −169 (Pinti et al., 2002; Zhang et al., 2006; Vasilescu et al.,
2004).
FAS receptor is expressed in the TCD4+ cell surface which is the
main target of HTLV-1 infection, thus the activation of this recep-
tor by interacting with its natural ligand FASLG may be induced
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y the viral infection (Debatin et al., 1994; Richardson et al., 1990;
hirono et al., 1989; Worner et al., 1990). The current results sug-
est that the average levels of the TCD4+ and TCD8+ lymphocytes
etween patients and control groups with the presence of the alle-
es FAS −670G, FASLG −124G or FASLG −169T, show no difference
hat implies in association of these polymorphisms, but the provi-
al load count showed statistically signiﬁcant difference according
o the genotype proﬁle. Considering that there was no signiﬁcant
ifference regarding viral load counts when assessing intra-group
alues, it is possible that the differences were attributed to the
linical status and not to the genetic background.
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